Johnson & Johnson (NYSE:JNJ) ranks among the 14 safe stocks to buy now for a starter stock portfolio. On March 2, BofA Securities boosted its price target for Johnson & Johnson (NYSE:JNJ) to $253 from ...
The fair value estimate for Johnson & Johnson has been adjusted from US$232.50 to US$237.29 per share, a small move that ...
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price is back in rally mode. It is still early in the game, but the Q2 results ...
Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
Zacks Investment Research on MSN
Johnson & Johnson (JNJ) could be a great choice
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent ...
Johnson & Johnson reports earnings on Wednesday. Investors may be paying attention to tariff-related developments more so than the company's actual growth rate. Historically, Johnson & Johnson has ...
Johnson & Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited ...
Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter. The pharma company also announced it will spin off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results